scholarly journals Qingkailing injection for the treatment of acute upper respiratory infection in children: a systematic review and meta-analysis

2017 ◽  
Vol 4 (3) ◽  
pp. 245-253
Author(s):  
Jiarui Wu ◽  
Dan Zhang ◽  
Yutong Wang ◽  
Xiaomeng Zhang ◽  
Shi Liu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Respiratory Infection ◽  
Meta Analysis ◽  
Upper Respiratory Infection ◽  
Qingkailing Injection ◽  
Upper Respiratory

scholarly journals TNF-α inhibitors can increase the risk of respiratory infection when used in rheumatism: a meta-analysis and systematic review

2020 ◽  
Author(s):  
Wenwen Luo ◽  
Luo Wenwen ◽  
Zhu Jialian ◽  
Cheng Xuan ◽  
Li Yun ◽  
...  
Keyword(s):  
Respiratory Infection ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Control Group ◽  
P Value ◽  
Upper Respiratory Infection ◽  
Serious Infection ◽  
Tnf Α ◽  
Serious Infections ◽  
Upper Respiratory

Abstract Background The risk of tumor necrosis factor-α(TNF-α) inhibitors (infliximab, etanercept, adalimumab) for the treatment of rheumatic diseases leading to infection events has not yet been established. This meta-analysis aims to assess the risk of developing serious infections of three TNF-α inhibitors for rheumatic diseases.Methods A systematic literature search of Pubmed, Embase and Cochrane Library was conducted through December 2018. Selecting the RCTs which subjects were diagnosed as rheumatoid diseases according to ACR criteria or other authoritative diagnostic criteria and over 18-year-old. Finally, RCTs with Jadad score greater than or equal to 4 were included in this meta-analysis. The Odds Ratio (OR), Confidence Interval (CI) and p value were calculated to assess the risk of serious infections. Results 34 RCTs involving 14166 subjects were included, including 11 RCTs for infliximab, 7 RCTs for etanercept, and 16 for adalimumab. Meta-analysis demonstrated that, with the pooled OR of 1.29 (95%CI 1.04 to 1.60), the TNF-α inhibitors group had a higher risk of serious infection than control group. In the subgroup analysis, infliximab and adalimumab had a higher risk of serious infection than control group, and the pooled ORs were 1.48 (p=0.03) and 1.47 (p=0.03), respectively. For other infections including pneumonia, upper respiratory infection, and nasopharyngitis, the risks of these adverse events were higher in experimental group than control group, while the risk of tuberculosis were not, with the pooled OR of 2.31 (p=0.08）.Conclusions TNF-α inhibitors, especially infliximab and adalimumab, can increase the risk of infections. Among the infections, pneumonia, upper respiratory infection and nasopharyngitis have higher risks in TNF-α inhibitors group than control group. As a result, we summarized that TNF-α inhibitors can increase the risks of respiratory infection when used in rheumatic disease. It is suggested that clinicians should pay attention to the prevention of respiratory infections when using TNF-α inhibitors, so as to achieve a better prognosis for patients with rheumatism.

The Effect Echinacea Purpurea Herbs in Reducing Symptoms of Upper Respiratory Infection: A Meta-Analysis

2020 ◽  
Author(s):  
Riska Fajar Fatony ◽  
◽  
Didik Gunawan Tamtomo ◽  
Hanung Prasetya ◽  
◽  
...  
Keyword(s):  
Tract Infection ◽  
Respiratory Tract ◽  
Respiratory Tract Infection ◽  
Respiratory Infection ◽  
Meta Analysis ◽  
Echinacea Purpurea ◽  
Upper Respiratory Tract Infection ◽  
Upper Respiratory Tract ◽  
Upper Respiratory Infection ◽  
Upper Respiratory

Background: Echinacea possibly reduces the effectiveness of corticosteroids, commonly used by asthmatics and for treating viral induced wheeze, and can cause hypersensitivity reactions in susceptible individuals. Treatment of the common cold in children with Echinacea has only been investigated in one randomized, double blind, placebo controlled trial to examine the efficacy and safety of Echinacea purpurea in children with upper respiratory tract infections. This study aimed to investigate the effect Echinacea purpurea herbs in reducing symptoms of upper respiratory infection. Subjects and Method: This was meta-analysis and systematic review. The study was conducted by collecting published articles from PubMed, Science Direct, and Google Scholar databases. The study subject was adults with upper respiratory infection. Intervention was Echinecea purpurea herbs extract with comparison placebo. The study outcome was decreased symptoms of upper respiratory tract infection. The inclusion criteria were full text, using English language, and using randomized controlled trial. The collected articles were selected by PRISMA flow chart. The quantitative data were analyzed using Revman 5.3 Results: A meta-analysis using 6 studies from United States resulted high heterogeneity between experimental groups (I2= 98%; p<0.001), so it conducted by random effect model (REM). This study showed that provision of Echinecea purpurea herbs extract reduced symptoms of upper respiratory tract infection than placebo (Mean Difference= -0.56; 95% CI= -0.91 to -0.22; p= 0.001). Conclusion: Echinecea purpurea herbs extract reduced symptoms of upper respiratory tract infection than placebo. Keywords: Echinacea purpurea herbs extract, upper respirstory infection Correspondence: Riska Fajar Fatony. Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java. Email: [email protected]. Mobile: +6289508588008. DOI: https://doi.org/10.26911/the7thicph.05.58

Andrographis Paniculata for the Treatment of Upper Respiratory Infection: A Systematic Review by the Natural Standard Research Collaboration

EXPLORE ◽  
2006 ◽  
Vol 2 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Benjamin Kligler ◽  
Catherine Ulbricht ◽  
Ethan Basch ◽  
Catherine DeFranco Kirkwood ◽  
Tracee Rae Abrams ◽  
...  
Keyword(s):  
Systematic Review ◽  
Respiratory Infection ◽  
Research Collaboration ◽  
Andrographis Paniculata ◽  
Upper Respiratory Infection ◽  
Upper Respiratory

Do Children Who Experience Laryngospasm Have an Increased Risk of Upper Respiratory Tract Infection?

1996 ◽  
Vol 85 (3) ◽  
pp. 475-480. ◽  
Author(s):  
Mark S. Schreiner ◽  
Irene O'Hara ◽  
Dorothea A. Markakis ◽  
George D. Politis
Keyword(s):  
Confidence Interval ◽  
Respiratory Infection ◽  
Odds Ratio ◽  
Signs And Symptoms ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Upper Respiratory Infection ◽  
Airway Surgery ◽  
Increased Risk ◽  
Upper Respiratory

Background Laryngospasm is the most frequently reported respiratory complication associated with upper respiratory infection and general anesthesia in retrospective studies, but prospective studies have failed to demonstrate any increase in risk. Methods A case-control study was performed to examine whether children with laryngospasm were more likely to have an upper respiratory infection on the day of surgery. The parents of all patients (N = 15,183) who were admitted through the day surgery unit were asked if their child had an active or recent (within 2 weeks of surgery) upper respiratory infection and were questioned about specific signs and symptoms to determine if the child met Tait and Knight's definition of an upper respiratory infection. Control subjects were randomly selected from patients whose surgery had occurred within 1 day of the laryngospasm event. Results Patients who developed laryngospasm (N = 123) were 2.05 times (95% confidence interval 1.21-3.45) more likely to have an active upper respiratory infection as defined by their parents than the 492 patients in the control group (P &lt; or = 0.01). The development of laryngospasm was not related to Tait and Knight's definition for an upper respiratory infection or to recent upper respiratory infection. Children with laryngospasm were more likely to be younger (odds ratio = 0.92, 95% confidence interval 0.87-0.99), to be scheduled for airway surgery (odds ratio = 2.08, 95% confidence interval 1.21-3.59), and to have their anesthesia supervised by a less experienced anesthesiologist (odds ratio = 1.69, 95% confidence interval 1.04-2.7) than children in the control group. Conclusion Laryngospasm was more likely to occur in children with an active upper respiratory infection, children who were younger, children who were undergoing airway surgery, and children whose anesthesia were supervised by less experienced anesthesiologists. Understanding the risk factors and the magnitude of the likely risk should help clinicians make the decision as to whether to anesthetize children with upper respiratory infection.

Sign in / Sign up

Export Citation Format

Share Document